Moreover, emerging evidence, suggest that alterations in the PPAR pathway at the molecular level are both early and late events in CKD and CKD progression mouse models [45,46] and fenofibrate treatment exerts nephroprotective effects thought the attenuation of inflammatory and fibrotic pathways [41,47,48]. Here, PPARA is linked to chronic kidney disease.